B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
β2-microglobulin (B2M) and Janus kinases 1 and 2 (JAK1/2) mutations have been suggested as genetic mechanisms of immune evasion for anti-programmed cell death protein 1 (PD-1) therapy. Whether B2M and JAK1/2 lose-of-function mutation can cause primary resistance to anti-PD-1 therapy in colorectal ca...
Main Authors: | Ding, P. (Author), Han, K. (Author), Hou, Z. (Author), Jiang, W. (Author), Li, D. (Author), Li, Y. (Author), Liao, L. (Author), Pan, Z. (Author), Sui, Q. (Author), Tang, J. (Author), Xiao, B. (Author), Zhang, C. (Author), Zhang, L. (Author), Zhang, R. (Author), Zhang, X. (Author), Zhou, C. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01) -
The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses
by: Guanglin Cui, et al.
Published: (2021-03-01) -
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
by: Na Luo, et al.
Published: (2018-06-01) -
Effects of Interferon on PD-1/PD-L1 and Treg Expression in JAK2 V617F-positive Myeloproliferative Neoplasms
by: ZHANG Lijun, et al.
Published: (2019-01-01) -
Colorectal Carcinogenesis: MSI-H Versus MSI-L
by: Timothy M. Pawlik, et al.
Published: (2004-01-01)